Regenerative Medical Technology Group, Inc. Details Expanded ISSCA AI(TM) Clinical Intelligence Platform, Including Protocol-Native Engine, Structured Data Assets, and Multi-Line Commercial Model

The article describes a physician-controlled lab-to-plan workflow incorporating ISSCA protocol ingestion, licensed technology and a clinic-facing SaaS and membership model. The design emphasizes that physicians retain clinical decision-making authority. No financial metrics, commercial terms, customer commitments or timeline were disclosed, limiting near-term market impact.